|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
A considerable number of studies have shown that plasma concentrations of FABP4 is increased in obesity and T2DM, and that circulating FABP4 levels are correlated with certain clinical parameters, such as body mass index, insulin resistance, and dyslipidemia.
|
30857223 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological modification of FABP4 function by specific inhibitors, neutralizing antibodies or antagonists of unidentified receptors would be novel therapeutic strategies for several diseases, including obesity, diabetes mellitus, atherosclerosis and cardiovascular disease.
|
30726793 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effects of HFD on obesity and insulin resistance in two distinct types of adipose-specific L-PGDS gene knockout (KO) mice: fatty acid binding protein 4 (fabp4, aP2)-Cre/L-PGDS <sup>flox/flox</sup> and adiponectin (AdipoQ)-Cre/L-PGDS <sup>flox/flox</sup> mice.
|
30760783 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum adipocyte fatty acid-binding protein (A-FABP) is closely correlated to metabolic disorders such as obesity and insulin resistance (IR).
|
30554468 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, chronic engagement of FABP4 under conditions of immunometabolic stress, such as obesity, exacerbates a number of immunometabolic diseases, including diabetes, asthma, cancer, and atherosclerosis.
|
30705117 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the subgroup of women combined with obesity and FABP4 ≥median, the measured OR was 9.83 (95% CI [4.76-16.13]; p < 0.001) for GDM compared to those without obesity and FABP4 <median.
|
30428456 |
2019 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Transgenic (Tg) mouse models overexpressing PHB (PHB-Tg) and a phospho-mutant PHB (mPHB-Tg) from the fatty acid binding protein-4 (Fabp-4) gene promoter display sex-neutral obesity; however, obesity-related insulin resistance and metabolic dysregulation are male-specific.
|
31118075 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fatty acid-binding protein-4 (FABP4) is an adipokine associated with obesity and signs of the metabolic syndrome.
|
31025416 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fatty acid binding protein 4 (FABP4) is a novel adipokine that is closely associated with obesity and metabolic diseases.
|
29549054 |
2018 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest FABP4, an FABP not normally expressed in the liver, can be synthesized and secreted by hepatocytes and HCC cells, and that FABP4 may play a role in regulating tumour progression in the underlying setting of obesity.
|
29171144 |
2018 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FABP4 is secreted from adipocytes in association with lipolysis, and an elevated circulating FABP4 level is associated with obesity, insulin resistance, and atherosclerosis.
|
28903937 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of FABP4 in peripheral macrophages via either molecular or pharmacologic mechanisms results in reduced obesity-induced inflammation via a UCP2-redox based mechanism.
|
28214555 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
AFABP may also be involved in fetal growth and the association between SGA status and obesity and metabolic syndrome in later life.
|
28324040 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, FABP4 may enhance PCa progression and invasiveness by upregulating matrix metalloproteinases and cytokine production in the PCa stromal microenvironment, especially under HFD or obesity.
|
29340091 |
2017 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous work has demonstrated that deletion of the adipocyte fatty acid-binding protein (FABP4/aP2) uncouples obesity from inflammation via upregulation of the uncoupling protein 2 (UCP2).
|
27795298 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
A-FABP-JAK2 axis may represent an important pathological pathway contributing to obesity-related inflammatory diseases.
|
28094778 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings reveal the FABP4/DNMT1 axis in the control of AML cell fate in obesity and suggest that interference with the FABP4/DNMT1 axis might be a new strategy to treat leukemia.
|
27885273 |
2017 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased circulating FABP4 level is associated with obesity, insulin resistance and atherosclerosis.
|
26754658 |
2016 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study is to evaluate the impact of FABP4 polymorphisms on FABP4 plasma levels and subclinical arteriosclerosis in patients with obesity, metabolic syndrome (MS) or type 2 diabetes (T2DM).
|
26141940 |
2015 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
We generated the aP2-promoter driven Timm44 transgenic (Tg) mouse model and investigated whether Timm44 Tg mice fed high-fat/high-sucrose (HFHS) chow are protected from type 2 diabetes and obesity.
|
25749183 |
2015 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
fabp4 is central to eight obesity associated genes: a functional gene network-based polymorphic study.
|
25280936 |
2015 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although none of these activities was significantly different between the obese and normal-weight children, lactonase activity was found to be positively correlated with HDL-cholesterol and ApoA1 levels and negatively correlated with myeloperoxidase and fatty acid-binding protein 4 levels.
|
23789921 |
2013 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association study showed a significant positive association of the promoter variant -844A/G with childhood obesity and biomarkers of obesity such as weight, body mass index (BMI), BMI Z-Score, and adipocyte fatty acid-binding protein, along with a tendency toward significance with insulin resistance biomarkers.
|
23641975 |
2013 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In obesity FABP4 expression was down-regulated (at both mRNA and protein levels), with its levels mainly predicted by ATGL and inversely by the HOMA-IR index.
|
23139800 |
2012 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of this study were to assess the relationship between FABP4 and inflammatory cytokines related to obesity, and to evaluate FABP4 mRNA expression in visceral and subcutaneous adipose tissue in non-diabetic morbidly obese women versus healthy lean women.
|
21257725 |
2011 |